Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eli Lilly (LLY) PT Lowered to $305 at BMO Capital
February 4, 2022 6:55 AM ESTBMO Capital analyst Evan David Seigerman lowered the price target on Eli Lilly (NYSE: LLY) to $305.00 (from $310.00) while maintaining an Outperform rating.
The analyst commented, "Donanemab concerns overshadow a solid quarter and set up into 2022. Despite solid set of 4Q21 results and reiterated... More
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
February 3, 2022 7:13 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales (beat versus FactSet for Trulicity, Taltz, Jardiance and Verzenio, among other... More
Eli Lilly pushes back timeline for Alzheimer's drug application
February 3, 2022 6:35 AM ESTBy Leroy Leo
(Reuters) - Eli Lilly and Co deferred its timeline to complete application for accelerated approval of its experimental Alzheimer's drug, saying it expects such an approval to make little difference with Medicare's limited coverage terms.
Shares of Eli Lilly fell 2.6% to $244.21 on Thursday, after the drugmaker said it would complete the application sometime later in 2022, pushing away from first quarter, its initial timeline.
The U.S. Centers for Medicaid and Medicare Services... More
Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Revenue Beats, Offers Guidance
February 3, 2022 6:26 AM ESTEli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.49, $0.34 better than the analyst estimate of $2.15. Revenue for the quarter came in at $8 billion versus the consensus estimate of $6.74 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2022 EPS of $8.50-$8.65, versus the... More
